A Combination of DNA Vaccines Targeting Human Papillomavirus Type 16 E6 and E7 Generates Potent Antitumor Effects

Overview

Journal Gene Ther

Date 2005 Sep 24

PMID 16177818

Citations 25

Authors

S Peng

T T Tomson

C Trimble

L He

C-F Hung

T-C Wu

Affiliations

Soon will be listed here.

Abstract

Human papillomavirus (HPV) infects large numbers of women worldwide and is present in more than 99% of all cervical cancers. HPV E6 and E7 are two viral oncoproteins that are consistently expressed in HPV infections and HPV-associated malignancies. We have previously developed DNA vaccines encoding calreticulin (CRT) linked either to HPV type 16 (HPV-16) E6 or to HPV-16 E7, both of which generated significant antitumor effects against E6- and E7-expressing tumors. In this study, we demonstrate that simultaneous vaccination of C57BL/6 mice or HLA-A2 transgenic mice with both CRT/E6 and CRT/E7 DNA vaccines generates significant E6- and E7-specific T-cell immune responses in vaccinated mice. Furthermore, combined vaccination with both CRT/E6 and CRT/E7 DNA generates significantly better therapeutic antitumor effects against HPV E6- and E7-expressing tumors than vaccination with either CRT/E6 DNA or CRT/E7 DNA alone. Our data suggest that it may be desirable to combine DNA vaccines targeting E6 with DNA vaccines targeting E7 to develop effective immunotherapeutic strategies for control of HPV infection and HPV-associated lesions in a clinical setting.

Citing Articles

Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant.

Zhou Y, Zhang T, Wang Z, Xu X Virol J. 2025; 22(1):3.

PMID: 39780219 PMC: 11707914. DOI: 10.1186/s12985-024-02604-7.

HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial.

Bakker N, Rotman J, van Beurden M, Zijlmans H, van Ruiten M, Samuels S J Immunother Cancer. 2021; 9(8).

PMID: 34341131 PMC: 8330588. DOI: 10.1136/jitc-2021-002547.

Model of Human Tongue Squamous Cell Lines Stably Transfected with Human Papillomavirus (HPV)16 E6 and E7 Genes and Biological Characteristic Analysis.

Lan Z, Jia Z, Guo H, Yang Z, Yang Z, Pan X Biomed Res Int. 2021; 2021:9968691.

PMID: 34239937 PMC: 8241518. DOI: 10.1155/2021/9968691.

Combination immunotherapy with two attenuated Listeria strains carrying shuffled HPV-16 E6E7 protein causes tumor regression in a mouse tumor model.

Su L, Zhang Y, Zhang X, Liu T, Liu S, Li Y Sci Rep. 2021; 11(1):13404.

PMID: 34183739 PMC: 8238941. DOI: 10.1038/s41598-021-92875-9.

Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease.

Da Silva D, Skeate J, Chavez-Juan E, Luhen K, Wu J, Wu C Vaccine. 2019; 37(22):2915-2924.

PMID: 31010714 PMC: 6586561. DOI: 10.1016/j.vaccine.2019.04.043.

References

Porgador A, Irvine K, Iwasaki A, Barber B, Restifo N, Germain R . Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med. 1998; 188(6):1075-82. PMC: 2212529. DOI: 10.1084/jem.188.6.1075. View

Ji H, Chang E, Lin K, Kurman R, Pardoll D, Wu T . Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer. 1998; 78(1):41-5. DOI: 10.1002/(sici)1097-0215(19980925)78:1<41::aid-ijc8>3.0.co;2-x. View

Peng S, Trimble C, He L, Tsai Y, Lin C, Boyd D . Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther. 2005; 13(1):67-77. PMC: 3181153. DOI: 10.1038/sj.gt.3302607. View

Chen C, Wang T, Hung C, Yang Y, Young R, Pardoll D . Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 2000; 60(4):1035-42. View

Gao Q, Singh L, Kumar A, Srinivasan S, Wazer D, Band V . Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells. J Virol. 2001; 75(9):4459-66. PMC: 114197. DOI: 10.1128/JVI.75.9.4459-4466.2001. View

Hung C, Cheng W, Hsu K, Chai C, He L, Ling M . Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 2001; 61(9):3698-703. View

Cheng W, Hung C, Chai C, Hsu K, He L, Ling M . Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001; 108(5):669-78. PMC: 209378. DOI: 10.1172/JCI12346. View

Munger K, Basile J, Duensing S, Eichten A, Gonzalez S, Grace M . Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 2001; 20(54):7888-98. DOI: 10.1038/sj.onc.1204860. View

Xiao F, Wei Y, Yang L, Zhao X, Tian L, Ding Z . A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther. 2002; 9(18):1207-13. DOI: 10.1038/sj.gt.3301788. View

10.

Trimble C, Lin C, Hung C, Pai S, Juang J, He L . Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine. 2003; 21(25-26):4036-42. DOI: 10.1016/s0264-410x(03)00275-5. View

11.

Kim T, Hung C, Boyd D, He L, Lin C, Kaiserman D . Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res. 2004; 64(1):400-5. DOI: 10.1158/0008-5472.can-03-1475. View

12.

Kim J, Hung C, Juang J, He L, Kim T, Armstrong D . Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. 2004; 11(12):1011-8. DOI: 10.1038/sj.gt.3302252. View

13.

Ellenson L, Wu T . Focus on endometrial and cervical cancer. Cancer Cell. 2004; 5(6):533-8. DOI: 10.1016/j.ccr.2004.05.029. View

14.

Peng S, Ji H, Trimble C, He L, Tsai Y, Yeatermeyer J . Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol. 2004; 78(16):8468-76. PMC: 479075. DOI: 10.1128/JVI.78.16.8468-8476.2004. View

15.

Feltkamp M, Smits H, Vierboom M, Minnaar R, de Jongh B, Drijfhout J . Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993; 23(9):2242-9. DOI: 10.1002/eji.1830230929. View

16.

Ressing M, Sette A, BRANDT R, Ruppert J, Wentworth P, Hartman M . Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 1995; 154(11):5934-43. View

17.

Bosch F, Manos M, Munoz N, Sherman M, Jansen A, Peto J . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87(11):796-802. DOI: 10.1093/jnci/87.11.796. View

18.

Wu T, Guarnieri F, Staveley-OCarroll K, Viscidi R, Levitsky H, Hedrick L . Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A. 1995; 92(25):11671-5. PMC: 40464. DOI: 10.1073/pnas.92.25.11671. View

19.

Lin K, Guarnieri F, Staveley-OCarroll K, Levitsky H, August J, Pardoll D . Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996; 56(1):21-6. View

20.

Dalal S, Gao Q, Androphy E, Band V . Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J Virol. 1996; 70(2):683-8. PMC: 189867. DOI: 10.1128/JVI.70.2.683-688.1996. View